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Abstrak 
 
 
Latarbelakang: Kanser Payudara Tanpa Jenis Spesifik (IBC NST) 
terbahagi kepada empat subtaip menggunakan ujian immunokimia tisu iaitu 
Estrogen Receptor (ER), Progesterone Receptor (PR) dan Human Epidermal 
Receptor 2 (HER2). Ia diklasifikasikan kepada Luminal A (LA), Luminal B (LB), 
HER2 overexpressed (HO) dan triple negative (TN). Pengkelasan St. Gallen 
2011 menyatakan penggunaan indeks proliferatif, Ki67 antibodi untuk 
menentukan subtaip LB daripada LA. LB mempunyai prognosis yang lebih teruk 
dan rawatan yang berbeza.  
Objektif: Kajian ini bertujuan untuk menentukan HER2 negatif subtaip 
Luminal B menurut Pengkelasan St Gallen 2011 menggunakan antigen Ki67 
dan membandingkan ciri-ciri klinikopatologi bagi setiap subtaip luminal. 
 Kaedah: Kes-kes IBC NST yang mempunyai spesimen biopsi tisu yang 
disusuli mastektomi diambil daripada arkib Hospital Queen Elizabeth di Kota 
Kinabalu, Sabah. Biopsi tisu LA diuji menggunakan antibody terhadap Ki67. 
Kes-kes LA dengan Ki67 ≥14% diklasifikasikan semula sebagai subtaip LB 
manakala Ki 67< 14% kekal sebagai LA. Perbandingan setiap subtaip luminal 
dengan tahap barah, saiz barah dan kewujudan metastasis ke noda limfa 
seterusnya dibuat. Analisis univariasi menggunakan regresi logistik mudah 
diadakan untuk menentukan peratusan ekspresi Ki67 dalam kes-kes IBC NST.  
Ujian McNemar’s digunakan untuk analisis kategori berkembar. Semua 
   
xi 
pengiraan dibuat menggunakan SPSS versi 22 dan nilai-p  <0.05 diset sebagai 
signifikan. 
Keputusan: LA adalah subtaip yang biasa (43%; 68/158), diikuti LB yang 
lebih agresif (33%; 52/158). Hanya 37 daripada 68 kes luminal A diuji dengan 
Ki67 disebabkan sampel yang terhad dan 43% (16/37) menunjukkan Ki67 ≥14% 
(dikelaskan semula sebagai subtaip LB). Penggunaan Ki67 memberikan 
perbezaan keputusan yang signifikan secara statistik (P<0.001; P<0.05). Walau 
bagaimanapun, subtaip LB menunjukkan keputusan statistik yang tidak 
signifikan apabila dibandingkan antara tahap, gred dan status noda limfa. 
Kesimpulan: Klasifikasi barah payudara menurut Pengkelasan St Gallen 
2011 menggunakan Ki67 antigen selain ER, PR and HER2 dalam mengenali 
kes subtaip LB, yang mempunyai prognosis yang lebih teruk. 
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Abstract 
 
 
Background: Invasive Breast Carcinoma of No Specific Type (IBC NST) 
is divided into four subtypes using Estrogen Receptor (ER), Progesterone 
Receptor (PR) and Human Epidermal Receptor 2 (HER2) immunohistochemistry 
markers. They are classified into Luminal A (LA), Luminal B (LB), HER2 
Overexpressed (HO) and Triple Negative (TN) subtype. The St. Gallen 2011 
Classification recognizes the use of Ki67 proliferative index to identify LB 
subtype from LA group. LB has a worse prognosis and different approach of 
treatment.  
Objective: This study aimed to identify HER2 negative LB subtype 
according to St Gallen Classification 2011 using Ki67 and to compare the 
clinicopathological features of different subtypes. 
Methods: Tissue biopsies of LA subtype were stained with antibody 
towards Ki67. LA cases with Ki67 ≥14% were reclassified as LB subtype. 
Luminal subtypes with corresponding stage (tumour size), histological grade and 
lymph node metastases were compared. Univariate analysis using simple 
logistic regression was performed to determine the percentage of Ki67 
expression among all IBC NST cases. McNemar’s test was used for paired 
categorical analysis. All calculations performed using SPSS version 22 and a p-
value of <0.05 was set to denote statistical significance. 
Results: LA is the most common subtype (43%; 68/158), followed by LB 
(33%; 52/158). Only 37 out of 68 cases were stained with Ki67 due to sample 
limitations. From these LA cases, 43% (16/37) showed Ki67 ≥14% (reclassified 
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as LB subtype). There was significant result when using Ki67 (P<0.001; 
P<0.05). However, LB subtype showed statistically insignificant result when 
compared with between stage, grade and lymph node status.  
Conclusion: The classification according to the St Gallen Classification 
2011 utilized Ki67 marker in addition to ER, PR and HER2 in identifying luminal 
B subtype cases, which have a worse prognosis.  
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CHAPTER 1: INTRODUCTION 
 
 
 
1.1 Literature review 
 
 
Breast cancer remains as the major cause of death for women in the 
21st century and the most common female cancer worldwide (Peter Boyle, 
2008). The aetiology and pathogenesis are diverse and there are still not well 
understood (Abdulkareem, 2013). It is the number one cause of death due to 
cancer in Malaysian women (Leong, 2007; Cheng Har Yip, 2006). The 
incidence varies among ethnicities in Malaysia, mostly affecting Chinese 
(Pathy et al., 2011). Malaysian women have a 1 in 20 chance of developing 
breast cancer during their lifetime whereas in Sabah, where the population is 
3.39 million with more than 30 ethnic groups, most cases presented with 
advanced disease (Agarwal et al., 2007; Benjamin Dak Keung Leong, 2007; 
Leong, 2007; Ibrahim et al., 2012; de Deus Moura et al., 2015). The 
percentage of breast cancer detected at stage I and II was 58% (Goldhirsch 
et al., 2011). To date, there was no specific study focusing on Invasive 
Breast Carcinoma of No Specific Type (IBC NST) in Sabah (CH Yip, 2014).  
 
The most significant classification of tumours of the breast was that 
produced by the World Health Organization (Hoda et al., 2009; Tavassoéli, 
2012; Sinn and Kreipe, 2013). IBC NST are tumours devoid of special 
features thus the designation NST (Edwin R. Fisher, 1975). The special types 
of invasive breast carcinoma includes tubular, cribriform, mucinous, 
medullary, lobular, metaplastic, adenoid cystic and invasive secretory 
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carcinoma (Page, 2003; Alessandra Fabbri, 2008; Sinn and Kreipe, 2013). 
IBC NST is further subclassified into molecular subtypes (Goldhirsch et al., 
2011; Malhotra et al., 2014). Different subtypes carry different prognosis and 
different treatments (Ferguson et al., 2013). Most typing is possible by way of 
studying the morphology on H&E staining whereby molecular study is the 
more accurate way of subtyping albeit costly (Eroles et al., 2012).  
 
Several studies have shown the heterogeneity of IBC NST and new 
classifications were produced that can alter management and outcome of 
patients (Goldhirsch et al., 2011; Hortobagyi, 2012a; Molloy et al., 2012). The 
most popular method of subtyping is by surrogating using 
immunohistochemistry staining (Cheang et al., 2009; Maisonneuve et al., 
2014). The importance is because of different response to therapy and the 
availability of specific targeted treatment using hormonal and 
chemotherapeutic agents (Lim and Winer, 2011; Boyle et al., 2013a). 
Different subtypes also carry different prognosis in term of metastasis and 
relapse (Guarneri et al., 2009; Kennecke et al., 2010; Voduc et al., 2010; 
Nuria Ribelles, 2013). 
 
 There are 4 subtypes of IBC NST according to the St Gallen 
classification 2011 (Goldhirsch et al., 2011) (Table 4). In previous 
classification each subtypes are characterized by the expression of hormonal 
receptors namely Estrogen Receptor (ER), Progesterone Receptor (PR) and 
Human Epithelial Receptor (HER2) on the tumour cells (Figure 1) (Onitilo et 
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al., 2009). In addition to ER, PR and HER2, the classification in 2011 
incorporates Ki67, a proliferative marker. Determining subtypes is important 
because of different prognosis and treatment modalities (Chen et al., 2014; 
Criscitiello et al., 2014). This study concentrates on the use of Ki-67 labelling 
index, as the means of identifying Luminal B (LB) subtype of IBC NST. Cases 
of Luminal A (LA) with Ki67 of 14% and more are classified as HER2 
negative LB.  
 
Determining luminal subtypes is a part of prognostic factor aimed to 
foresee the outcome of patients irrespective of treatment. On the other hand, 
predictive factors intend to assess the outcome of patients associated with 
sensitivity or resistance to therapy. Thus, a predictive factor is also a 
therapeutic target such as in the case of ER and HER2. Evaluation by 
immunohistochemistry (IHC) of ER, PR, and HER2 status represent 
consolidated and standardized prognostic factors. ER, PR and HER2 status 
are also validated predictive markers. Other accepted prognostic markers are 
represented by morphological findings such as tumour size (stage), grade, 
lymphovascular invasion, lymph node status and Ki67 (Rampaul et al., 2001; 
Faratian and Bartlett, 2008; Hoda et al., 2009; Song et al., 2011; Haroon et 
al., 2013; Inic et al., 2014; Francisco Acevedo, 2015; Liu et al., 2015). There 
is potential for Ki67 as a predictive factor as well, in the case where patients 
with high Ki67 benefit from adjuvant chemotherapy (Criscitiello et al., 2014). 
However there were contradicting study regarding this (Ferguson et al., 
2013). 
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1.1.1 Stage 
 
Pathological staging of breast cancer takes into account the size of the 
tumour, denoted as a capital T, and can be staged as T1 to T4. Tumours 
may be measured clinically or pathologically; the pathologic size of the lesion 
may be measured either macroscopically or microscopically. The clinical size 
of a breast lesion as measured by mammograms or physical examination 
may differ from the macroscopic pathologic size. It is possible that the 
presence of a macroscopically measurable lesion has a poorer outcome 
(Singletary, 2002; Edge, 2010).  
 
1.1.2 Histologic grade 
 
Besides staging, histologic grading system also plays an important 
prognostic factor. The most commonly used grading system, the Nottingham 
Histologic Score (also referred to as Elston-Ellis modification of Scarff-Bloom-
Richardson grading system), combines nuclear grade, tubule formation, and 
mitotic rate to classify invasive breast carcinomas into three groups that are 
highly correlated with survival (Table 1) (Meyer, 2005; Hoda et al., 
2009). Survival for patients with well-differentiated grade 1 carcinomas 
gradually declines to 70% at 24 years. In contrast, most deaths for poorly 
differentiated grade 3 carcinomas occur in the first 10 years, and 45% of 
patients survive long-term. Patients with moderately differentiated grade 2 
carcinomas have better survival initially, but their long-term survival is only 
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slightly better than grade 3 carcinomas (Ellis., 1991; Leslie W. Dalton, 1994; 
S. E. Pinder, 1998; Howayda Abd El All, 2001). A grade of low, intermediate 
or high is obtained through a composite sum by assigning a ‘score’ based on 
the nuclear assessment, mitotic index assessment, and tubular assessment 
(Table 1). The nuclear assessment is based on the nuclear pleomorphism 
within the invasive cells. The tubular assessment refers to an approximate, 
quantitative account of the amount of cell groupings that remain in their 
normal ‘tubular’ shape. The less the percentage of tubular structures in 
comparison to other shapes, the higher the score. The mitotic index refers to 
patterns of cell division through assessing the numbers of dividing daughter 
cells, measured per square millimetre. Mitoses are only counted in the 
invasive area of the tumour (V. Le Doussal, 1989; Meyer, 2005). 
 
1.1.3 Lymph node involvement 
 
Axillary lymph node status at the time of diagnosis is the most 
significant and durable prognostic factor in breast cancer patients. To date, 
only nodal status has been consistently associated with survival outcomes in 
occult primary breast cancer (Ivkovic-Kapicl et al., 2006; Hoda et al., 2009). 
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1.1.4 The St Gallen Classification 
 
Clinicians, pathologists and researchers convene in St Gallen, 
Switzerland to give a consensus regarding breast cancer treatment including 
what is theoretically feasible in patient risk stratification, treatment and daily 
practice management (Giuseppe Curigliano, 2013). In the earlier consensus 
given in 1998, patients with breast cancer were classified into different risk 
groups according to lymph node status, tumour size, grade, receptor status 
and age (Table 2). Such classifications were made to guide oncologists in 
giving adjuvant chemotherapy as studies have shown that most patients 
benefit from chemotherapy regardless of lymph node status (Salisbur, 2002) 
(Table 3). A study has also shown that the use of the older St Gallen 
classification have led to the overuse of adjuvant chemotherapy. However, 
such overuse may be overcame by using Ki67 for LA cases thus recognizing 
HER2 negative LB, who are proven to benefit from chemotherapy 
(Goldhirsch et al., 2011). The St Gallen classification in 2011 has 
recommended adjuvant chemotherapy for LB and not for LA in IBC NST. 
This is because the LB subtype proliferative index quantified by surrogate 
IHC marker has been proven to be associated with more aggressive cancer 
subtype and can be classified into LB despite HER2 marker being negative 
(Table 5).  
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1.1.5 Hormonal receptors 
 
All breast carcinomas are characterized by expression of ER and PR 
receptors as well as the status of HER2. These, in relation to other 
clinicopathological parameters, defines treatment recommendations for each 
individual case (D.O. Shapochka, 2012). Approximately 70–80% of IBC NST 
are ER positive, and between 15–30% of cases are HER2 positive. 
Determining ER and HER2 status is considered as standard care for all 
invasive breast carcinoma as these biomarkers are predictive for response of 
patients to hormonal treatment and/or HER2-inhibiting medication (Wolff et 
al., 2007; Hammond et al., 2010). 
 
1.1.6 Luminal A subtype 
 
ER positive family was named luminal class since they have the same 
molecular signature strongly resembling luminal cells of breast duct (Taylor-
Papadimitriou et al., 1989). LA is the most common subtype (Kumar et al., 
2015). Whilst ER positive family, negative for HER2 is called LA, those 
expressing HER2 is called LB. It is important to differentiate these two 
subtypes because LA has been associated with a favourable prognosis 
(Perez-Rodriguez, 2015) and LB, less favourable prognosis (Sotiriou et al., 
2003).  
 
  
 
  
8 
1.1.7 Luminal B subtype 
 
A study by (Cheang et al., 2009) has shown that LB family is 
associated with higher histological grade (grade 3), compared to lower grade 
(grade 1 and 2). This subtype has a poorer prognosis (Tang et al., 2015). 
Distinguishing LB subtype using Ki67 expression is of critical value since it 
would isolate a group of patients in early breast carcinoma that could benefit 
from adjuvant chemotherapy (Lim and Winer, 2011; Pavlakis et al., 2012). 
New targeted therapy are also being developed specifically for LB subtype 
(Ben Tran, 2011). 
 
1.1.8 HER2 Overexpressed subtype 
 
Several studies demonstrated that HER2 overexpression is correlated 
with reduced survival. Overexpression is associated with relative resistance 
to tamoxifen therapy or alkylating agent (Wang and Hung, 2001). In contrast 
to previous data from Western countries that showed triple negative subtype 
to be the worst in term of prognosis, a study in South Korea showed that 
HER2 overexpressing breast cancers displayed the worst prognosis among 
the various subgroups, and not triple negative subtype. This finding proved 
that there is more to breast cancer of different subtypes in different 
population groups and the need for more study in local population as not all 
data demonstrated in Western population applies to Asians, and this might 
affect treatment and prognostication (Mattes et al., 2015). 
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1.1.9 Triple negative subtype 
 
Triple negative breast cancer (TNBC) is an aggressive clinical 
phenotype characterized by lack of expression (or minimal expression) of ER 
and PR as well as an absence of HER2 overexpression. TNBC is not 
amenable to treatment with hormone therapy or the anti-HER2 monoclonal 
antibody trastuzumab, and systemic treatment options are limited to cytotoxic 
chemotherapy. Unlike patients with ER/PR positive or HER2 overexpressing 
disease, systemic treatment options for patients with TNBC are limited to 
cytotoxic chemotherapy due to the lack of a molecular target (Siziopikou and 
Cobleigh, 2007; Nishimura and Arima, 2008; Cicin et al., 2009). Despite its 
chemosensitivity, TNBC is still associated with a poor prognosis. The median 
time to death among patients with TNBC was also shorter than that with 
other subtypes (Cicin et al., 2009). 
 
1.1.10 Ki67 
 
Recently, the immunohistochemical expression of Ki67 has replaced 
mitotic counting in assessing the proliferation of neoplastic cells. There is a 
lot of rising evidence on its importance as a prognostic and predictive marker 
of responsiveness to therapy and as a dynamic biomarker of treatment 
efficacy (O. Gottardi, 1993; Graef et al., 2008; Miglietta et al., 2013). In early 
breast carcinoma, high Ki67 is an independent factor for worse prognosis as 
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shown by significantly shorter overall and disease-free survival (Goldstein, 
2004 ; Jung et al., 2009; Zong et al., 2014; Marrazzo et al., 2015). High Ki67 
was predictive of more benefit from adjuvant chemotherapy (Elzawahry et al., 
2013) even in cases without lymph node metastasis (Andre et al., 2015). The 
prognostic role of Ki67 in early breast cancer was indicated in large sample 
study (Goldhirsch et al., 2011). (Dowsett et al., 2011) and (Nishimura et al., 
2010) mentioned the potential use of Ki67 for prognosis, predict 
responsiveness or resistance to endocrine or chemotherapy and as a 
dynamic biomarker of treatment efficacy. A study found that Ki67 expression 
is inversely related to their sensitivity to first line endocrine therapy (Graef et 
al., 2008). The St Gallen International Expert Consensus on the primary 
therapy of early breast cancer 2011 defined a cut-off point of 14% for the 
distinction between luminal A and luminal B (HER2 negative) tumours 
(Dowsett et al., 2011; András Vörös, 2014; Ono et al., 2015). 
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1.2 Rationale of the study 
 
Very few data regarding Sabah population is available, yet the 
numbers of breast cancer patients are increasing and they always presented 
late. This study involves population where presentation is late, thus 
association between Ki67 index and late presentation will be observed. 
Subtyping is important because of different treatment approach; Luminal B 
has a much worse prognosis than Luminal A, when taking Ki67 into 
consideration; it has a role of being an independent prognostic factor. We 
also wanted to see the significance of taking into account Ki67 in determining 
luminality in Sabah population, whether a significant percentage from the 
Luminal A subtype has high Ki67 index. 
 
1.3 Objectives 
 
Objective 1: To reclassify and compare luminal A & B IBC NST using Ki67 
index.  
 
Objective 2: To compare grade, stage and lymph node metastasis of luminal 
A and Luminal B IBC NST. 
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CHAPTER 2: STUDY PROTOCOL 
 
2.1 Study design and method 
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menghantar 'Continuing Review Form' selewat-lewatnya 2 bulan sebelum tamat tempoh kelulusan 
ini bagi memperbaharui kelulusan etika. Pihak tuan juga perlu mengemukakan laporan tamat kajian 
dan juga laporan mengenai "A// adverse events, both serious and unexpected' kepada 
Jawatankuasa Etika & Penyelidikan Perubatan, KKM jika berkenaan. Borang-borang berkaitan 
boleh dimuat turun daripada Iaman web MREC (http://www.nih.gov.my/mrec) 
Sekian terima kasih. 
BERKHIDMAT UNTUK NEGARA 
(DATO' DR CHANG KlAN MENG) 
Pengerusi 
Jawatankuasa Etika & Penyelidikan Perubatan 
Kementerian Kesihatan Malaysia 
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2.3 Ethical consideration 
 
 
Confidentiality of the data was taken into account. Ethic approval was 
obtained from Ethics Approval; Medical Research & Ethics Committee NMRR 
(National Medical Research Register); NMRR-14-269-20213. 
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CHAPTER 3: MANUSCRIPT 
 
 
 
3.1 Introduction 
 
 
Breast cancer is the most common cancer in female worldwide (Peter 
Boyle, 2008) and is the number one cause of death due to cancer in 
Malaysian women (Benjamin Dak Keung Leong, 2007; Cheng Har Yip, 
2006). The incidence varies among ethnicities in Malaysia, mostly affecting 
Chinese (Bhoo Pathy et al., 2011). With recent progress in studies pertaining 
to the detailed aspects of the disease which include molecular testing, new 
classification has emerged that alter management and outcome of patient, 
therefore benefiting the patients (Goldhirsch et al., 2011; Hortobagyi, 2012b). 
The introduction of genetic array testing has allowed breast cancer to be 
further subtyped by different methods (Sorlie, 2004; Molloy et al., 2012). The 
most popular one is by approximation using immunohistochemistry staining 
(Maggie C. U. Cheang 2009). This is important due to the different response 
to therapy and the availability of specific targeted treatment using hormonal 
and chemotherapeutic agents (Boyle et al., 2013b).  
 
This study concentrated on the use of immunohistochemical definition 
of estrogen receptor (ER) and progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER2) oncogene, as well as Ki67 
labelling index; a marker of cell proliferation, as the means of identifying 
tumour subtypes according to St Gallen expert consensus 2011(Goldhirsch 
et al., 2011).  
  
 
  
16 
Most studies that have been done usually revolve around western 
population where detection of breast cancer is during the early stage. There 
is however a difference in hormonal status when the disease is at its more 
advanced stage. By concentrating on Malaysian population in Sabah, North 
Borneo, where detection and intervention is at a late stage, this study seeks 
to find out differences of hormonal status as compared to early stages. This 
study reclassified Luminal A (LA) and Luminal B (LB) subtypes of Invasive 
Breast Carcinoma of No Special Type (IBC NST) using Ki67 according to St 
Gallen International Consensus 2011 (Goldhirsch et al., 2011). Associations 
between subtypes and other clinicopathological characteristics such as 
ethnicity, stage, histological grade and status of axillary lymph node were 
analysed.  
 
This study aims to classify Invasive Breast Carcinoma of No Specific 
Type (IBC NST) according to St Gallen consensus 2011 with emphasis on 
Ki67 index. There are 2 specific objectives involved; 1) To reclassify and 
compare luminal A & B IBC NST using Ki67 index. 2) To compare grade, 
stage and lymph node metastasis of luminal A and Luminal B IBC NST 
(Hammond et al., 2010). 
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3.2 Materials and Methods 
 
 
This study is a cross sectional study design. It utilized cases of breast 
biopsies (core biopsies or excision biopsies) that were followed by 
mastectomy specimens only, with final histopathological diagnosis of IBC 
NST, for the period of June 2009-December 2014 in the Pathology 
Department, Hospital Queen Elizabeth, Kota Kinabalu. Only cases with 
biopsies followed by mastectomy were included. Search query was 
conducted using Lab Information System (LIS) at the Pathology Department, 
Hospital Queen Elizabeth, Kota Kinabalu, Sabah.  
 
Cases that fulfilled the inclusion criteria but the corresponding 
paraffinised tissue blocks are not available, missing and inadequate for serial 
sections were excluded from the analysis for the objectives of this study. 
Biopsies that were not followed by mastectomy and mastectomies without 
prior biopsies were also excluded. 
 
Clinicopathological parameters including age, ethnicity, tumour grade, 
tumour size (stage), lymph nodes involvement and ER and PR status, and 
HER2 expression were obtained from the histopathological reports (Tamaki 
et al., 2010). In this study only the pathological stage (T), which is determined 
by tumour size was considered. 
 
Independent pathologists of the Anatomic Pathology Department had 
examined these surgical specimens and formal pathology reports had been 
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issued within that period. Only suitable cases that met the inclusion criteria 
were chosen and the paraffin blocks were then retrieved from the archives. 
 
3.2.1 Laboratory work 
 
Standard immunoperoxidase procedures were followed for tissue 
sections obtained from each case. The selected single representative block 
for each case was sectioned to 4-micron thickness. Two sections were 
obtained from all LA cases (ER+ and or PR+, HER2-) according to data 
obtained from patient’s record in LIS. This section was subjected to H&E and 
Ki67 staining. Ki67 staining was done using K2 antibody (BondTM) (Leica, 
2009). 
 
The obtained sections were placed on heater at 60°C for at least 1 
hour to facilitate the adherence of tissue onto the slides. Leica Autostainer 
System performed the next steps automatically. For Ki67 IHC staining 
BondTM Ready-to-Use Primary Antibody Ki67 (K2) was utilised. The 
application was performed by Bond-Max Fully Automated IHC system (Leica) 
using according to the manufacturer’s IHC protocol. The demonstration of 
human Ki67 nuclear antigen is achieved by first, allowing the binding of Ki67 
(K2 antibody) to the section, and then visualizing this binding using the 
reagents provided in the detection system. The use of these products, in 
combination with an automated Bond system, reduces the possibility of 
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human error and variability resulting from individual reagent dilution, manual 
pipetting and reagent application (Leica, 2009).  
 
3.2.2 Microscopic analysis 
 
Using a bright-field microscope (Olympus CX31), microscopic 
evaluation of the slides immunostained for Ki67 was performed blinded from 
the clinicopathological data of the study subjects. H&E slides were examined 
to re-evaluate and to verify the diagnosis and location of tumour cells when 
compared to Ki67 slides. Ki67 proliferative index was reviewed by main 
researcher (supervisor) and co-supervisors at a separate time to avoid bias. 
Each case was divided into 2 groups; Ki67 equal or more 14% and Ki67 less 
than 14% (Dowsett et al., 2011). ER, PR and HER2 hormonal qualitative 
status by IHC were obtained from the formal reports. The quantitative scores 
whether performed or not were disregarded.  
 
3.2.3 Ki67 
 
Slides stained with Ki67 were analysed according to 
Recommendations from the International Ki67 in Breast Cancer Working 
Group (Dowsett et al., 2011). Only nuclear staining plus mitotic figures which 
were stained by Ki67 were  incorporated into the Ki67 score that is defined as 
the percentage of positively stained cells among the total number of 
  
 
  
20 
malignant cells scored. When the staining is homogenous, at least three 
randomly selected high-power (×40 objective) fields were selected.  
 
3.2.4 Statistical analysis 
 
Data was entered and statistical analysis was conducted by using test 
on Statistical Package for Social Sciences (SPSS) program version 22. 
Univariate analysis using simple logistic regression was performed. 
McNemar’s test was used for paired categorical analysis. A p-value of <0.05 
was set to denote statistical significance. 
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3.3 Results 
 
3.3.1 Clinicopathological data of the study subjects 
 
One hundred and fifty eight cases of IBC NST, which met the inclusion 
criteria (cases with biopsy followed by mastectomy), were included in this 
study. Clinicopathological data of the study subjects were summarized in 
(Table 6). Distributions of the age, ethnicity and institutions were shown in 
(Table 7) and (Figure 2), (Figure 4), (Table 8) and (Figure 3). Analysis for 
different subtypes and clinicopathological factors were summarized in (Table 
9) and (Figure 5). Majority of the study subjects were natives. The mean age 
of the patients was 50.4 years with the age ranging from 28 to 78 years 
(Figure 2). This is comparable to data from peninsular Malaysia. All the cases 
included were those where biopsies were taken prior to mastectomies with 
axillary clearance. Almost half of the tumours (49.4%) had tumour size larger 
than 20mm but smaller than 50mm. Lymph node metastasis was found in 
majority of cases (64.6 %). More than half of the tumours (55.1%) were grade 
3 tumours. ER, PR and HER2 status were positive in 74.7%, 62.7% and 
45.6% of the cases respectively (Table 6).  
 
Most cases were from Kota Kinabalu (62.7%; 99/158), followed by 
Sandakan and Tawau. Other cases are from Keningau, Lahad Datu, Labuan 
and Beaufort (Table 8 and Figure 3). The main referral centre is in Hospital 
Queen Elizabeth, Kota Kinabalu where mastectomies were performed on a 
regular basis. Whereas in the other centres, it is carried out from time to time 
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by visiting surgeons. All the specimens were sent for examination to the 
Pathology Department of Queen Elizabeth Hospital in Kota Kinabalu.  
 
The highest prevalence was observed among natives (78.5%; 
124/158) followed by Chinese (18.4%; 29/158). Majority of cases were at late 
stage during presentation (stage 2 and 3; 94.7%; 148/158) and of high grade 
(grade 2 and 3; 93.7%; 148/158). Cases with lymph node metastasis were 
64.6% (102/158). 
 
3.2.2 Ki67 Proliferative Index and Luminal B Subtype 
 
LA is the most common subtype (44%; 68/158), followed by LB  (33%; 
52/158) (Table 9 and Figure 5). Only 37 LA cases were stained with Ki67 due 
to sample limitations. From these stained LA cases, 43% (16/37) showed 
Ki67 ≥14% (Image 1) (reclassified as LB subtype) (Table 11). Cases of Ki67 
less than 14% remain as LA subtype (Image 2). The difference in number of 
cases between LA and LB with and without the use of Ki67 is statistically 
significant (<0.001) using McNemar’s Test (Table 12). There was no 
significance when LA and LB subtypes with and without Ki67 staining were 
compared against grade, stage and lymph node status (Table 13).  
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3.4 Discussion and limitation 
 
In general, breast cancer remains the most common cancer among 
Malaysian women, which accounted for 31% of newly diagnosed cancer 
cases in women registered in the National Cancer Registry (NCR) for the 
year 2003-2005. The risk differs among the major ethnic groups in Malaysia; 
about 1 in 16 Chinese, 1 in 17 Indian and 1 in 28 Malay women will develop 
breast cancer in their lifetime (NCR, 2007). In Malaysia, breast cancer is 
more common among Chinese as compared to Malay. However, in this study 
it was difficult to divide the study subjects strictly according to ethnicity. Due 
to the demographical situation in Sabah, which comprises of up to 36 ethnics, 
where mixed marriage is common (Suraya Sintang, 2011), all of the subjects 
that are not Chinese, Indian or Non-Malaysians were grouped together as 
natives. There is lack of information and standardisation when it comes to 
determining the ethnicity of a subject who is a result of interracial marriage. 
There is no concrete guidance in Malaysia whether to follow paternal or 
maternal ethnicity. Thus such subject was lumped together as natives. It is 
also doubtful whether dividing the subjects according to ethnicities will have 
any significance in term of determining the incidence of the disease, as 
studies tried to separate subjects according to race or ethnicities to find 
lifestyle and cultural influences on the aetiology or pathogenesis 
(Kurebayashi et al., 2007). Whereby in Sabah, the population is more 
integrated in terms of lifestyle that is of any connection to the risk factors 
such as food, breast-feeding or contraception (B Norsa’adah, 2005). 
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In comparison with other studies, this study have focused mainly on 
the cases of IBC NST and only those cases where histopathological 
diagnosis was made by biopsy before being followed by mastectomy. Most 
studies failed to specify the samples used either biopsy or mastectomy 
specimen. In some centres in Malaysia hormonal receptors are tested on 
biopsy specimens whereas in others it is tested on mastectomies. Most 
literature reported cases in western countries. There are very few studies 
done on IBC NST cases in Sabah. Because most of IBC NST cases in 
Sabah are at a late stage, the cases presented earlier, mainly of Luminal A 
subtype that could have benefited from chemotherapy when categorized as 
Luminal B seems to be disregarded. As we are moving toward better medical 
care, earlier presentation of breast cancer cases are expected in the future.  
 
Most of the results (grade, lymph node metastasis) shown were not 
statistically significant as anticipated at the beginning of the study (Table 13). 
Several factors may have contributed to this. As discussed, the limited 
sample size was a major setback. Only 37 cases were stained for subtyping. 
However, in comparison with the other studies done on larger samples, this 
study only collected cases where biopsy was performed prior to mastectomy. 
The majority of subjects presented in stage 2 and 3 (87%), this is when 
taking into account that these patients had a biopsy before mastectomy. The 
possible main reason behind this is late detection due to lack of access and 
awareness. However, there were cases of straightforward breast cancer that 
were diagnosed clinically and managed by mastectomy, without first 
